471 related articles for article (PubMed ID: 26428666)
1. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings.
Jack CR; Wiste HJ; Weigand SD; Knopman DS; Mielke MM; Vemuri P; Lowe V; Senjem ML; Gunter JL; Reyes D; Machulda MM; Roberts R; Petersen RC
Brain; 2015 Dec; 138(Pt 12):3747-59. PubMed ID: 26428666
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
Yau WW; Tudorascu DL; McDade EM; Ikonomovic S; James JA; Minhas D; Mowrey W; Sheu LK; Snitz BE; Weissfeld L; Gianaros PJ; Aizenstein HJ; Price JC; Mathis CA; Lopez OL; Klunk WE
Lancet Neurol; 2015 Aug; 14(8):804-813. PubMed ID: 26139022
[TBL] [Abstract][Full Text] [Related]
3. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
4. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
[TBL] [Abstract][Full Text] [Related]
5. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Rocca WA; Knopman DS; Mielke MM; Lowe VJ; Senjem ML; Gunter JL; Preboske GM; Pankratz VS; Vemuri P; Petersen RC
Lancet Neurol; 2014 Oct; 13(10):997-1005. PubMed ID: 25201514
[TBL] [Abstract][Full Text] [Related]
6. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
7. EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
Gaubert S; Raimondo F; Houot M; Corsi MC; Naccache L; Diego Sitt J; Hermann B; Oudiette D; Gagliardi G; Habert MO; Dubois B; De Vico Fallani F; Bakardjian H; Epelbaum S;
Brain; 2019 Jul; 142(7):2096-2112. PubMed ID: 31211359
[TBL] [Abstract][Full Text] [Related]
8. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
[TBL] [Abstract][Full Text] [Related]
9. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
[TBL] [Abstract][Full Text] [Related]
10. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.
Wirth M; Villeneuve S; Haase CM; Madison CM; Oh H; Landau SM; Rabinovici GD; Jagust WJ
JAMA Neurol; 2013 Dec; 70(12):1512-9. PubMed ID: 24166579
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
Palmqvist S; Mattsson N; Hansson O;
Brain; 2016 Apr; 139(Pt 4):1226-36. PubMed ID: 26936941
[TBL] [Abstract][Full Text] [Related]
12. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
13. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease.
Papp KV; Amariglio RE; Mormino EC; Hedden T; Dekhytar M; Johnson KA; Sperling RA; Rentz DM
Neuropsychologia; 2015 Jul; 73():169-75. PubMed ID: 26002757
[TBL] [Abstract][Full Text] [Related]
14. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.
Knopman DS; Jack CR; Wiste HJ; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
JAMA Neurol; 2013 Aug; 70(8):1030-8. PubMed ID: 23797806
[TBL] [Abstract][Full Text] [Related]
15. Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration.
Jack CR; Wiste HJ; Knopman DS; Vemuri P; Mielke MM; Weigand SD; Senjem ML; Gunter JL; Lowe V; Gregg BE; Pankratz VS; Petersen RC
Neurology; 2014 May; 82(18):1605-12. PubMed ID: 24706010
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
17. Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals.
Vassilaki M; Christianson TJ; Mielke MM; Geda YE; Kremers WK; Machulda MM; Knopman DS; Petersen RC; Lowe VJ; Jack CR; Roberts RO
Ann Neurol; 2017 Jun; 81(6):871-882. PubMed ID: 28543731
[TBL] [Abstract][Full Text] [Related]
18. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.
Jack CR; Knopman DS; Weigand SD; Wiste HJ; Vemuri P; Lowe V; Kantarci K; Gunter JL; Senjem ML; Ivnik RJ; Roberts RO; Rocca WA; Boeve BF; Petersen RC
Ann Neurol; 2012 Jun; 71(6):765-75. PubMed ID: 22488240
[TBL] [Abstract][Full Text] [Related]
19. Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers.
Roberts RO; Knopman DS; Syrjanen JA; Aakre JA; Vassilaki M; Kremers WK; Mielke MM; Machulda MM; Graff-Radford J; Geda YE; Vemuri P; Lowe V; Jack CR; Petersen RC
Neurology; 2017 Nov; 89(20):2039-2048. PubMed ID: 29030451
[TBL] [Abstract][Full Text] [Related]
20. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study.
Jack CR; Therneau TM; Wiste HJ; Weigand SD; Knopman DS; Lowe VJ; Mielke MM; Vemuri P; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2016 Jan; 15(1):56-64. PubMed ID: 26597325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]